2C-T-7-NBOMe Stats & Data

Human data on 2C‑T‑7‑NBOMe are extremely sparse; guidance is inferred from NBOMe‑class reports and the 2C‑T‑7 parent’s risk profile. NBOMes are highly potent 5‑HT2A agonists with sub‑milligram active doses; mismeasurement and rapid redosing are major overdose vectors—never eyeball and prefer volumetric dosing with clear labels to prevent accidental ingestion. Multiple NBOMes (25I/25C) have caused severe vasoconstriction, hypertensive crises, seizures, hyperthermia, rhabdomyolysis, and deaths—several specifically after insufflation; intranasal use should be avoided. 2C‑T‑7 (parent) has documented insufflation fatalities at tens of milligrams, underscoring extra caution with thio‑phenethylamines; do not combine this NBOMe with 2C‑T‑x drugs or stimulants. NBOMes on blotter are often sold as LSD; field tests that are positive for LSD (e.g., Ehrlich/NIK) and UV fluorescence support true lysergamide, whereas NBOMes typically do not react the same—test before use and do not assume blotter is LSD. Some NBOMe salts may have partial oral bioavailability, but effects are inconsistent and delayed; swallowing is not a safety measure and can tempt risky redosing. HPBCD‑complexed NBOMe products are more bioavailable and can be much stronger than expected at the same nominal dose; if unknown, start well below customary ranges. Allergy test ≤25–50 µg buccal is prudent due to idiosyncratic reactions reported across the class. Maintain hydration and temperature awareness, monitor for cold/numb extremities or chest pressure (possible vasospasm), and treat seizures or collapse as medical emergencies. Due to microgram potency, store away from others, clearly labeled, and never pre‑load nasal sprays; several fatalities followed ‘one drop’ intranasal exposures of unknown concentration.